Investigating how MHC-E presents diverse antigens for AIDS vaccine development
Official title: Non-canonical epitope presentation and antigen processing by MHC-E
Funded at Oregon Health & Science University · NIH-10935982 · Data updated 2026-11-12
This study is looking at how a special molecule helps the immune system recognize different pieces of viruses, with the goal of creating a better vaccine for AIDS, and it could lead to new ways to boost the body's defenses against HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 25, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $701,712 |
| NIH project number | 5R01AI175459-02 |
| Project ID | NIH-10935982 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for HIV infection or those living with HIV who may benefit from improved vaccine strategies.
✕Less likely to help
Patients who are not at risk for HIV or those who have already achieved viral suppression with current therapies may not receive direct benefits from this research.
What this research studies
This research focuses on understanding how a specific molecule, MHC-E, presents a variety of antigens to the immune system, particularly in the context of developing a vaccine for AIDS. The study utilizes a modified cytomegalovirus (CMV) to elicit immune responses that can control and potentially clear the simian immunodeficiency virus (SIV). By examining the mechanisms behind MHC-E's ability to present non-canonical peptides, the research aims to uncover new strategies for enhancing T cell immunity against HIV. Patients may benefit from insights gained that could lead to more effective vaccines.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective AIDS vaccine that enhances immune responses against HIV.
How similar studies have gone: Other research has shown promise in using unconventional approaches to vaccine development, but this specific focus on MHC-E is relatively novel.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Fruh, Klaus J — Oregon Health & Science University
- Study coordinator: Fruh, Klaus J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.